Aldeyra Therapeutics reported statistically significant improvements in liver function markers in a four‑patient, one‑month, single‑arm Phase 2 study of its oral RASP modulator ADX‑629 for alcohol‑associated hepatitis. The study showed a P‑value of 0.001 for the Model for End‑Stage Liver Disease (MELD) score, P < 0.0001 for triglyceride levels, and P < 0.0001 for C‑reactive protein, with no serious adverse events.
Despite the encouraging signal, the company confirmed that it is discontinuing further clinical development of ADX‑629, except for investigator‑sponsored testing in Sjögren‑Larsson Syndrome. The Phase 2 results are being used as a proof‑of‑concept milestone for the RASP modulator platform.
Aldeyra shifted its focus to next‑generation molecules. ADX‑248 is being prioritized for metabolic inflammation, including obesity and hypertriglyceridemia, and is expected to file an IND in 2026. ADX‑246 is slated for dry age‑related macular degeneration and is also expected to file an IND in 2026. The company also highlighted other late‑stage programs, including reproxalap for dry eye disease and allergic conjunctivitis, and ADX‑2191 for primary vitreoretinal lymphoma and retinitis pigmentosa.
The pipeline update extends the company’s projected cash runway into the second half of 2027, supported by a strong liquidity position with a current ratio of 2.86 and a cash ratio of 2.77.
The results and strategic shift underscore Aldeyra’s commitment to advancing its RASP modulator platform while reallocating resources to newer candidates with broader therapeutic potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.